What education should be given to a patient with herpes zoster involving the eye?

Patient Education for Herpes Zoster with Eye Involvement

Patients with herpes zoster ophthalmicus must be educated about warning signs requiring immediate ophthalmologic attention, the importance of early antiviral treatment within 72 hours of rash onset, and the critical need for recombinant zoster vaccine (RZV) for future prevention in those aged 50 and older.

Critical Warning Signs to Report Immediately

Educate patients to contact their ophthalmologist urgently if they experience:

• Eye redness (the most common ocular symptom, occurring in 40.7% of cases) 1
• Eye pain or irritation (present in 32.7% of cases) 1
• Decreased vision or blurred vision
• Increased floaters in the eye 2
• Any new eye symptoms even if painless, as recurrent attacks may be asymptomatic 3

Patients should be instructed to assess their visual acuity regularly using simple techniques such as reading newsprint 2. This self-monitoring is essential because some complications develop without pain.

Timing of Treatment is Critical

• Antiviral medications (acyclovir, valacyclovir, or famciclovir) are most effective when started within 72 hours of rash onset 4
• Early treatment prevents ocular involvement and permanent vision loss 4
• Even if the 72-hour window has passed, patients should still seek treatment as antivirals may still provide benefit

Risk Factors for Poor Visual Outcome

Patients should understand they are at higher risk for vision loss if they:

• Are 60 years of age or older 1
• Have nasociliary nerve involvement (indicated by lesions on the tip of the nose - Hutchinson's sign) 1

These patients require particularly close ophthalmologic monitoring.

Potential Complications

Educate patients about possible sequelae that may develop:

• Postherpetic neuralgia (chronic debilitating pain)
• Keratitis (corneal inflammation)
• Uveitis (intraocular inflammation)
• Optic neuritis (rare but can cause rapid vision loss) 5
• Chronic ocular inflammation
• Permanent vision loss 4
• Conjunctival scarring that can lead to eyelid malposition 6

Follow-up Requirements

• Patients require careful follow-up evaluation by an ophthalmologist to detect and treat possible late-onset complications such as scarring and immune reactions 7
• Regular monitoring is needed even after initial symptoms resolve
• Some complications may develop weeks after the initial infection

Vaccination for Prevention

Strongly recommend recombinant zoster vaccine (RZV/Shingrix) for all patients 50 years and older without contraindications 8. Key vaccination points:

• RZV is preferred over the live zoster vaccine (96% vs 70% efficacy) 8
• RZV is recommended even for those who previously received the live vaccine 8
• Vaccine effectiveness for preventing HZO is 67-93% 9
• The vaccine is given as a 2-dose series 10
• Patients should coordinate with their primary care physician for vaccination

Hygiene and Infection Control

While herpes zoster is less contagious than chickenpox, patients should:

• Keep lesions covered to prevent transmission 7
• Avoid physical contact with others, especially:
  • Pregnant women who have never had chickenpox
  • Immunocompromised individuals
  • Infants who haven't been vaccinated
• Understand that the virus can be transmitted to susceptible individuals who may then develop chickenpox (not shingles)

Medication Adherence

• Complete the full course of antiviral therapy as prescribed
• If topical antivirals are prescribed, use exactly as directed
• Never use topical corticosteroids without ophthalmologic consultation and concurrent antiviral therapy 7
• Inform all healthcare providers about the history of herpes zoster ophthalmicus, especially before receiving corticosteroids for any reason 3

Long-term Considerations

• Some patients may require suppressive antiviral therapy to prevent recurrence, though evidence for this practice is limited 9
• Patients with a history of HZO should emphasize this to any physician prescribing immunosuppressive therapy 3
• Consider prophylactic antivirals if undergoing procedures or treatments that may trigger reactivation

Prognosis

Reassure patients that most achieve good visual outcomes with prompt treatment, with median final visual acuity of 20/25 1. However, emphasize that this favorable outcome depends on early recognition and treatment of complications.